Lung Cancer

The Road MAP to Targeted Therapy in Squamous-Cell Carcinoma: Lung Cancer Master Protocol (SWOG S1400) Overview

Lung cancer is the leading cause of cancer-related death worldwide. More than 85% of cases of the disease are classified as non–small-cell lung cancer (NSCLC), with a predicted 5-year survival rate of 16%.1 The battle against lung cancer entered a new era with the identification of actionable genomic aberrations in [ Read More ]

Case: Molecular Pathways in Non–Small Cell Lung Cancer

Recent guidelines call for molecular testing for 2 specific actionable alterations in any patient with non–small cell lung cancer (NSCLC) with an adenocarcinoma component: EGFR mutation and ALK fusion. Testing should be performed at the time of diagnosis. A case demonstrating standard of care for the management of a patient [ Read More ]

Care Pathway for NSCLC Cuts Chemotherapy Charges

Implementing a clinical pathway for stage IV non–small-cell lung cancer (NSCLC) led to a reduction in chemotherapy drug charges at the Cleveland Clinic, reported James Stevenson, MD. A pathway for the management of patients with nonsquamous EGFR wild-type, ALK-negative stage IV NSCLC was developed between October 2013 and July 2014. [ Read More ]

Expanding Options for EGFR-Mutant Non–Small Cell Lung Cancer with Afatinib

Targeted treatments have proved to be clinically successful and represent the realization of personalized medicine’s potential. In non–small cell lung cancer (NSCLC), molecularly targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib have shown dramatic responses in patients with activating mutations.1-3 EGFR [ Read More ]

FDA Approves Opdivo (Nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non–Small Cell Lung Cancer

Bristol-Myers Squibb Company announced that the Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Opdivo is the first and only PD-1 (programmed death-1) therapy to [ Read More ]

The Need for Immunotherapeutic Approaches for Lung Cancer

Non–small cell lung cancer is one of the major cancer types for which new immune-based cancer treatments are currently in development Lung cancer is the second most common cancer in both men and women (not counting skin cancer); in men, prostate cancer is more common, whereas in women, breast cancer [ Read More ]

FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Cancer Immunotherapy MPDL3280A (Anti–PD-L1) in Non–Small Cell Lung Cancer

Second FDA Breakthrough Therapy Designation for MPDL3280A Following Bladder Cancer in 2014 Genentech, a member of the Roche Group, announced today that it has received a second Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its in­vestigational cancer immunotherapy MPDL3280A (anti–PD-L1). The designation was granted for [ Read More ]

Navigating the Molecular Testing Landscape in Lung Cancer

Experts discuss how they use mutational testing The expansion of tumor genetic profiling into the clinic has led to effective, targeted treatments for patients but created a daily dilemma for oncologists: What to do with the results of these tests? At the 15th Annual International Lung Cancer Congress, a panel [ Read More ]

Resistance to Targeted Molecular Therapies in NSCLC

Over the past decade, there has been enormous progress in our understanding of the molecular pathogenesis of non–small cell lung cancer (NSCLC), in particular among patients with lung adenocarcinoma. Approximately 60% of these patients’ tumors will be oncogene addicted.1 Those with mutated EGFR and ALK rearrangements can be treated with [ Read More ]

Crizotinib Miracle: A Nursing Perspective

For every nurse there is a patient who you will never forget; the details of that story will not blur over time. In the developing era of personalized medicine, there is that 1 patient whose story I will not easily forget. It is the story of a 24-year-old male medical [ Read More ]

Sign me up!
Friends link: prep4certs
070-411 Braindumps
VCP-550 Braindumps
70-483 Braindumps
70-462 Braindumps
400-101 Braindumps
070-461 Braindumps